- 20628-09-5Ethanone,1-(7-methoxy-2,2-dimethyl-2H-1-benzopyran-6-yl)-
- 20628-27-7Acetamide,N-[2-(methylsulfonyl)phenyl]-
- 2062-84-22H-Benzimidazol-2-one,1-[1-[4-(4-fluorophenyl)-4-oxobutyl]-4-piperidinyl]-1,3-dihydro-
- 2062-98-8Propanoyl fluoride,2,3,3,3-tetrafluoro-2-(1,1,2,2,3,3,3-heptafluoropropoxy)-
- 20629-90-73H-Pyrazol-3-one,2-(2-chlorophenyl)-1,2-dihydro-5-methyl-
- 2063-17-4Butanoic acid,4-chloro-4,4-difluoro-3-oxo-, ethyl ester
- 20633-67-4Calycosin-7-O-beta-D-glucoside
- 20634-12-2Tetraammineplatinum dinitrate
- 206346-33-0Benzenepropanenitrile,4-iodo-β-oxo-
- 206347-30-07-bromo-2,3-dihydrobenzofuran
Hot Products
- 30909-51-4Decanoic acid,2-[4-[3-[2-(trifluoromethyl)-9H-thioxanthen-9-ylidene]propyl]-1-piperazinyl]ethylester
- 42751-79-1Superfloc C 573
- 698-87-31-PHENYL-2-PROPANOL
- 9011-14-72-Propenoic acid,2-methyl-, methyl ester, homopolymer
- 66004-57-7Hgh (176-191)
- 29761-21-5Isodecyl diphenyl phosphate
- 168316-95-8Spinosad
- 6842-15-5Propylene tetramer
- 104987-11-3Tacrolimus
- 141-53-7Sodium formate
- 8001-54-5Quaternary ammonium compounds, alkylbenzyldimethyl, chlorides
- 9003-39-8Povidone
- 10161-34-9Trenbolone acetate
- 402957-28-2Telaprevir
- 68-19-9Cyanocobalamin
|
Basic Information |
|
Post buying leads |
|
Suppliers |
|
Cas Database |
| Name |
Pimozide |
EINECS | N/A |
| CAS No. | 2062-78-4 | Density | 1.224g/cm3 |
| PSA | 41.03000 | LogP | 5.79490 |
| Solubility | 2.9mg/L(30 oC) | Melting Point |
214-218° |
| Formula | C28H29 F2 N3 O | Boiling Point | °Cat760mmHg |
| Molecular Weight | 461.555 | Flash Point | °C |
| Transport Information | N/A | Appearance | N/A |
| Safety | Poison by ingestion, intravenous, and intraperitoneal routes. An experimental teratogen. Experimental reproductive effects. When heated to decomposition it emits toxic fumes of NOx and F−. | Risk Codes | 22 |
| Molecular Structure |
|
Hazard Symbols |
|
| Synonyms |
2-Benzimidazolinone,1-[1-[4,4-bis(p-fluorophenyl)butyl]-4-piperidyl]- (7CI,8CI);1-(1-(4,4-Bis(4-fluorophenyl)butyl)-4-piperindinyl)-1,3-dihydro-2H-benzimidazol-2-one;1-[1-[4,4-Bis(p-fluorophenyl)butyl]-4-piperidyl]-2-benzimidazolinone;1-[4,4-Bis(p-fluorophenyl)butyl]-4-(2-oxo-1-benzimidazolinyl)piperidine; NSC170984; Orap; Pimozide; Primozide; R 6238 |
Article Data | 5 |
Pimozide Synthetic route
- 20662-53-7
4-(2-keto-1-benzimidazolinyl)piperidine
- 2062-78-4
pimozide
| Conditions | Yield |
|---|---|
| With sodium carbonate; potassium iodide In 1,3-dioxolane-4-methanol at 80℃; for 7h; | 97.5% |
- 51787-79-2
1,1-bis(-4-fluorophenyl)-4-iodobutane
- 20662-53-7
4-(2-keto-1-benzimidazolinyl)piperidine
- 2062-78-4
pimozide
| Conditions | Yield |
|---|---|
| With sodium carbonate In dichloromethane; acetonitrile at 80℃; for 12h; | 71% |
| With sodium carbonate In 1,2-dichloro-ethane; acetonitrile for 12h; Reflux; Inert atmosphere; | 62% |
- 61668-03-9
1,1'-(but-1-ene-4,4-diyl)bis(4-fluorobenzene)
- 2062-78-4
pimozide
| Conditions | Yield |
|---|---|
| Multi-step reaction with 2 steps 1.1: Schwartz's reagent / tetrahydrofuran / 2 h / 20 °C / Inert atmosphere 1.2: 0 - 20 °C / Inert atmosphere 2.1: sodium carbonate / acetonitrile; 1,2-dichloro-ethane / 12 h / Reflux; Inert atmosphere View Scheme |
| Conditions | Yield |
|---|---|
| Multi-step reaction with 3 steps 1.1: iodine; 3-dodecyl-2-iodo-1-methyl-1H-imidazol-3-ium hexafluoroantimonate / nitromethane / 2 h / 20 °C / Inert atmosphere 2.1: Schwartz's reagent / tetrahydrofuran / 2 h / 20 °C / Inert atmosphere 2.2: 0 - 20 °C / Inert atmosphere 3.1: sodium carbonate / acetonitrile; 1,2-dichloro-ethane / 12 h / Reflux; Inert atmosphere View Scheme |
| Conditions | Yield |
|---|---|
| Multi-step reaction with 3 steps 1: 1,10-Phenanthroline; copper(II) bis(trifluoromethanesulfonate); fac-tris(2-phenylpyridinato-N,C2')iridium(III); sodium phosphate / acetonitrile / 48 h / 23 °C / Sealed tube; Inert atmosphere; Irradiation 2: 1H-imidazole; iodine; triphenylphosphine / dichloromethane / 0.5 h / 20 °C 3: sodium carbonate / acetonitrile; dichloromethane / 12 h / 80 °C View Scheme |
- 2062-78-4
pimozide
| Conditions | Yield |
|---|---|
| Multi-step reaction with 3 steps 1: 1,10-Phenanthroline; copper(II) bis(trifluoromethanesulfonate); fac-tris(2-phenylpyridinato-N,C2')iridium(III); sodium phosphate / acetonitrile / 48 h / 23 °C / Sealed tube; Inert atmosphere; Irradiation 2: 1H-imidazole; iodine; triphenylphosphine / dichloromethane / 0.5 h / 20 °C 3: sodium carbonate / acetonitrile; dichloromethane / 12 h / 80 °C View Scheme |
Pimozide Chemical Properties
IUPAC Name: 3-[1-[4,4-bis(4-Fluorophenyl)butyl]piperidin-4-yl]-1H-benzimidazol-2-one
Synonyms: 1-[1-[4,4-Bis(p-Fluorophenyl)butyl]-4-piperidyl]-2-benzimidazolinone ; 1-[4,4-Di-(4-Fluorophenyl)butyl]-4-(2-oxo-1-benzimidazolinyl)piperidine ; 1-{1-[4,4-Bis(4-Fluorophenyl)butyl]-4-piperidinyl}-1,3-dihydro-2H-benzimidazol-2-one ; 1-{1-[4,4-bis(4-Fluorophenyl)butyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one
Product Categories: Organics;Dopamine receptor
CAS NO: 2062-78-4
Molecular Formula of Pimozide (CAS NO.2062-78-4) :C28H29F2N3O
Molecular Weight of Pimozide (CAS NO.2062-78-4) :461.55
Molecular structure of Pimozide (CAS NO.2062-78-4) :
EINECS: 218-171-7
Index of Refraction: 1.596
Surface Tension: 47.2 dyne/cm
Density: 1.224 g/cm3
Storage temp: 2-8°C
Solubility : DMSO: 18 mg/mL
Pimozide Uses
Pimozide (CAS NO.2062-78-4) is used in its oral preparation in schizophrenia and chronic psychosis (on-label indications in Europe only), Tourette syndrome and resistant tics (Europe, USA and Canada). In Germany the 1mg tablet is indicated for the treatment of some forms of reactive depression.
Pimozide Toxicity Data With Reference
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| dog | LD50 | intravenous | 32mg/kg (32mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 5, Pg. 106, 1974. | |
| dog | LD50 | oral | 40mg/kg (40mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | Arzneimittel-Forschung. Drug Research. Vol. 18, Pg. 261, 1968. |
| guinea pig | LD50 | oral | 189mg/kg (189mg/kg) | BEHAVIORAL: TREMOR BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | Arzneimittel-Forschung. Drug Research. Vol. 18, Pg. 261, 1968. |
| man | TDLo | oral | 7714ug/kg/15W (7.714mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: FLUID INTAKE KIDNEY, URETER, AND BLADDER: URINE VOLUME INCREASED | Journal of Clinical Pyschopharmacology. Vol. 12, Pg. 140, 1992. |
| mouse | LD50 | intraperitoneal | 1070mg/kg (1070mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 5, Pg. 106, 1974. | |
| mouse | LD50 | intravenous | 14mg/kg (14mg/kg) | "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972Vol. -, Pg. 288, 1972. | |
| mouse | LD50 | oral | 228mg/kg (228mg/kg) | BEHAVIORAL: ATAXIA | Collection of Czechoslovak Chemical Communications. Vol. 42, Pg. 1179, 1977. |
| mouse | LD50 | subcutaneous | > 16gm/kg (16000mg/kg) | BRAIN AND COVERINGS: RECORDINGS FROM SPECIFIC AREAS OF CNS SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE | Kiso to Rinsho. Clinical Report. Vol. 6, Pg. 629, 1972. |
| rabbit | LD50 | intravenous | 22mg/kg (22mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 5, Pg. 106, 1974. | |
| rabbit | LD50 | oral | 40mg/kg (40mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 5, Pg. 106, 1974. | |
| rat | LD50 | intraperitoneal | 350mg/kg (350mg/kg) | Drugs in Japan Vol. 6, Pg. 639, 1982. | |
| rat | LD50 | intravenous | 90mg/kg (90mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 5, Pg. 106, 1974. | |
| rat | LD50 | oral | 1100mg/kg (1100mg/kg) | Drugs in Japan Vol. 6, Pg. 639, 1982. | |
| rat | LD50 | subcutaneous | > 11gm/kg (11000mg/kg) | BRAIN AND COVERINGS: RECORDINGS FROM SPECIFIC AREAS OF CNS SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE | Kiso to Rinsho. Clinical Report. Vol. 6, Pg. 629, 1972. |
Pimozide Safety Profile
Poison by ingestion, intravenous, and intraperitoneal routes. An experimental teratogen. Experimental reproductive effects. When heated to decomposition it emits toxic fumes of NOx and F−.
Hazard Codes 
Xn
Risk Statements 22
R22:Harmful if swallowed.
Safety Statements 36
S36:Wear suitable protective clothing.
RIDADR 3249
WGK Germany 3
RTECS DE1750000
HazardClass 6.1(b)
PackingGroup III
Pimozide Specification
Contraindications and precautions:
1.Contraindicated in patients taking citalopram (Celexa) and escitalopram (Lexapro) due to prolongation of the QTc interval, as per the FDA.
2.Patients with prominent agitation or anxiety
3.Depressed patients
4.Severe intoxication with alcohol, opiates, and psychoactive drugs (e.g. antidepressants, benzodiazepines)
5.Preexisting Parkinson's disease
6.Comedication with nefazodone, clarithromycin and vetoconazol (see below under interactions)
7.Caution: Anticonvulsive treatment in epileptic patients should not be interrupted. Pimozide may in principle lower the seizure-threshold.
8.Caution: Patients under 18 yrs. of age. Side-effects may be particularly frequent and severe. Treatment should be started with low initial dose and the dose increased very slowly.
What can I do for you?
Get Best Price
